Avacta will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the ESMO 2026 Congress. avacta.com/avacta-to-present… #AVCT

Christina Coughlin, CEO, and Brian Hahn, CFO, will provide a live presentation relating to the Interim Results via Investor Meet Company on 15 Oct 2026, 16:00 BST. avacta.com/notice-of-interim… #AVCT

Avacta today publishes its unaudited interim results for the six months ended June 30, 2026. avacta.com/interim-results-f… #AVCT

Avacta's pre|CISION® platform has been honored by the Pharma Industry Awards UK 2026, winning the Research and Development Achievement Award. avacta.com/the-precision-pla… #AVCT

We’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd) at the AACR Conference on Pancreatic Cancer. avacta.com/the-focus-01-clin… #PancreaticCancer #preCISION #AVCT #NextGenLoading

Ask a scientist why they stay in oncology and you will usually hear about a "wow moment". The people behind pre|CISION® share theirs, from the first tumor to plasma data to a new molecule from idea to IND in 12 months. Watch the video here: avacta.wistia.com/s/8pc1j0fx… #AVCT

In episode 16 of the R&D Spotlight, the team discusses initial clinical data for AVA6103, pre|CISION® controlled-release exatecan, with two key clinical findings demonstrating proof of mechanism. avacta.wistia.com/s/51r2o75h… #NextGenLoading #AVCT

We have achieved clinical proof of mechanism for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, in the Phase 1 FOCUS-01 trial. Clean safety profile through 3 dose levels, and clinical PK closely matches preclinical modeling. avacta.com/avacta-achieves-c… #NextGenLoading #AVCT

Avacta today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee. avacta.com/avacta-appoints-m… #AVCT

Avacta announces that it has received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company has elected to settle in cash. avacta.com/accelerated-amort… #AVCT

Share Option Awards to Management Team at Avacta. avacta.com/share-option-awar… #AVCT

Avacta Academy, Episode 5: Taking a New Drug to the Clinic, Bench to Bedside. Meet the Avacta clinical team and hear how a medicine travels from the bench, through the IND and into the clinic, then back to the bench to shape the next candidate. avacta.wistia.com/s/tchseuwq… #AVCT

Today is #WorldHeadAndNeckCancerDay. Head and neck cancers, including salivary gland cancer, remain hard to treat. Our pre|CISION® platform and lead program AVA6000 are designed to target the tumor while sparing healthy tissue. #Oncology #HopeWithoutCompromise

In this Episode of the R&D Spotlight Series, Chris sits down with two members of the clinical team to preview the dataset coming in 2H 2026 demonstrating the sustained release mechanism of action with AVA6103. avacta.wistia.com/s/gqu44mn1… #AVCT

Avacta Academy - Episode 4. The Nuts and Bolts of Drug Development Explained, Breaking Down Pharmacokinetics. avacta.wistia.com/s/ttkprtba… #AVCT

Accelerated Amortized Payment of Convertible Bond Installment. avacta.com/accelerated-amort… #AVCT

We’re delighted to welcome Dr. Patrick Vink to Avacta’s Board as Non-Executive Deputy Chairman and Senior Independent Director. Patrick brings decades of pharma leadership at a key time for our pre|CISION® pipeline. avacta.com/avacta-appoints-h… #AVCT

BIO International 2026: Faridoxorobicin update with Avacta CEO @coughlin582. avacta.wistia.com/s/xi4ktvnh… #AVCT

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference. avacta.com/avacta-reports-pl… #AVCT

Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer. avacta.com/avacta-announces-… #AVCT